FilingSEC EDGAR6-K
NovaBridge Biosciences Reports Increased Net Loss For First Half Of 2026
· SEC accepted
StageEarnings Release
Filing content
The company reported a net loss of $37.9 million for the first half of 2026, driven by increased research and development and administrative expenses.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…